Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• Andhra Pradesh Approves Rs 500 Crore Port, Shipbuilding Cluster
• Amazon Eyes Faster Content Production With AI
• Why India Is Emerging as a Second Home for Multinationals
• Indigo Shares Slip 2% as CCI Orders Further Investigation 
• Concord Control Wins KAVACH 4.0 Order; Stock Jumps 4%

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.